621 studies on Semaglutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
If successful, this trial could identify a novel dietary supplement, AMPK Charge+®, that effectively improves glycemic control in individuals with prediabetes or Type 2 Diabetes. The potential for AMPK Charge+® to enh…
Successfully managing the gastrointestinal side effects of incretin-based anti-obesity medications is crucial for improving patient compliance and achieving optimal weight loss outcomes. This study's findings could es…
This study is crucial for understanding how lifestyle interventions like endurance exercise can complement pharmacological treatments such as semaglutide in managing Type 2 Diabetes. The key implication is that a comb…
This comprehensive meta-analysis provides strong evidence that GLP-1 RAs are safe and effective for managing metabolic complications in kidney transplant recipients. The significant improvements in glycemic control, w…
This case reinforces the critical importance of considering drug-induced pancreatitis in patients presenting with acute abdominal pain while on GLP-1 receptor agonists like Semaglutide. It highlights that even at stan…
This systematic review provides strong, synthesized evidence supporting the neuroprotective potential of GLP-1 receptor agonists in Alzheimer's disease, moving beyond individual study observations. The consistent find…
These findings are profoundly significant, as they demonstrate semaglutide's potential to not only improve metabolic health and liver steatosis but also to reverse biological aging at an epigenetic level. This suggest…
This study highlights a critical safety consideration for patients undergoing free flap breast reconstruction who are also using GLP-1 RAs. The observed increase in serious wound complications, particularly flap necro…
This study provides crucial economic evidence for healthcare payers and policymakers in the US, suggesting that the superior efficacy of tirzepatide translates into significant long-term health benefits and a favorabl…
This research provides crucial real-world evidence suggesting that semaglutide may not only manage obesity and type 2 diabetes but also potentially offer protective or beneficial effects on skeletal health, particular…
This research highlights the profound benefits of GLP-1 receptor agonist therapy in adolescents with obesity, demonstrating not just weight reduction but a critical improvement in body composition by preferentially re…
This study holds significant promise for improving long-term outcomes for adolescents undergoing bariatric surgery, a population often facing unique challenges in weight management. If semaglutide proves effective as …
This large-scale, real-world study is crucial for understanding the broader impact of semaglutide beyond controlled clinical trials, especially given its widespread use. The findings are expected to solidify the evide…
This Phase 4 clinical trial is crucial because it directly compares an established standard-of-care drug, metformin, with a newer, highly effective incretin therapy, semaglutide, in a real-world setting. The findings …
Developing new, potentially improved formulations of existing, effective drugs is crucial for enhancing patient convenience, adherence, and broader accessibility. If oral semaglutide D proves to be equally safe and ef…
The completion of this large Phase 3 trial is a significant milestone, as it represents a robust effort to explore a novel therapeutic avenue for Alzheimer's disease. If the results demonstrate a positive effect, it c…
Understanding the pharmacokinetic equivalence between daily and weekly dosing of semaglutide is crucial for optimizing drug development and patient care. If comparable steady-state exposure was achieved with daily adm…
This study holds significant promise by exploring the potential for a novel, enhanced therapeutic approach for managing complex metabolic disorders like obesity and Type 2 Diabetes. By combining a specially formulated…
This research provides crucial, granular insights into the stability and efficacy of Salcaprozate Sodium as an oral absorption enhancer under diverse physiological conditions. Understanding how various GI factors affe…
This study highlights a critical safety signal, suggesting that GLP-1 receptor agonists may be associated with an increased risk of depressed mood and suicidal ideation in real-world settings. This finding underscores…
This comprehensive review underscores Semaglutide's robust potential as an effective pharmacological intervention for chronic weight management in non-diabetic adults. The consistent and substantial weight loss, coupl…
Understanding drug-drug interactions is paramount for patient safety, especially with the increasing use of novel weight-loss medications like CagriSema. Many patients with obesity rely on medications such as atorvast…
This study is critically important because semaglutide (NN9535) is a widely used and highly effective treatment for Type 2 Diabetes. Understanding its pharmacokinetic profile in patients with renal impairment is vital…
While specific results for the OASIS 3 trial are currently pending publication, this Phase 3 study was designed to demonstrate significant body weight reduction. Based on the established efficacy of semaglutide as a G…
This Phase 2 trial is highly significant as it explores a potential novel adjunctive therapy for Type 2 Diabetes patients who are not adequately controlled by current GLP-1-based treatments. If icovamenib proves effec…
Demonstrating the clinical comparability of drug products from different manufacturing processes is crucial for ensuring consistent drug quality, safety, and patient outcomes globally. This study's findings, once rele…
Preserving lean muscle mass during rapid weight loss is critical for maintaining metabolic rate, improving insulin sensitivity, and preventing weight regain, especially in individuals with Type 2 Diabetes Mellitus. Th…
Understanding the precise impact of dosing variations on oral semaglutide pharmacokinetics is crucial for optimizing patient outcomes and adherence. This study provides robust data that reinforces the importance of cu…
The findings from this study are crucial because they will inform the safe and effective use of AD109 in a growing population of OSA patients who are also managing their weight or diabetes with GLP-1 medications. If A…
This study provides compelling evidence that tirzepatide, a dual GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist, is significantly more effective than semaglutid…
This comprehensive review underscores the significant potential of GLP-1 receptor agonists as a novel therapeutic strategy for stroke prevention, particularly in patients with type 2 diabetes and obesity. Their abilit…
This case report highlights the potential efficacy and safety of GLP-1 receptor agonists (GLP1RAs), specifically semaglutide, in managing the challenging glycemic control associated with mitochondrial diabetes in pedi…
This study's findings are highly significant as they highlight the potential for semaglutide, a widely utilized medication, to improve fertility prospects within a challenging patient population. Obesity-related infer…
Improved device design, particularly through automation, can significantly enhance patient safety and adherence for chronic conditions requiring frequent self-injection, such as type 2 diabetes and obesity. Reducing c…
This study provides crucial evidence that semaglutide is highly effective and well-tolerated in young adults with Type 2 Diabetes, a population facing unique challenges in disease management. The significant improveme…
This study provides robust real-world evidence suggesting a neuroprotective role for GLP-1 RAs, potentially offering a novel strategy for Parkinson's disease prevention or delaying its onset. These findings could pave…
This study provides compelling preclinical evidence that Semaglutide, a widely used GLP-1 receptor agonist, possesses significant neuroprotective properties against ischemic brain injury by targeting ferroptosis. The …
This Phase 3 study, consistent with other trials, further validates semaglutide 2.4 mg as a highly effective pharmacological intervention for the treatment of obesity and overweight. The robust and sustained weight lo…
This follow-up study is critical for understanding the sustained impact of semaglutide on cardiovascular health and weight management after treatment cessation. The insights gained could inform long-term treatment str…
This pilot study is crucial because it addresses a significant unmet need for effective smoking cessation strategies in Type 2 diabetes patients, a group at high risk for cardiovascular complications. If semaglutide p…
The successful completion of this Phase 3 trial suggests semaglutide 2.4 mg could represent a significant advancement in the management of obesity and prediabetes. If the full results confirm substantial weight loss a…
If BGM0504 demonstrates comparable or superior efficacy to semaglutide with a favorable safety profile, it could represent a significant new therapeutic option for managing Type 2 Diabetes. This could provide a valuab…